chronic hepatitis B
Conditions
Interventions
tenofovir alafenamide group:Oral tenofovir alafenamide
Sponsors
Ningbo Huamei Hospital, University of Chinese Academy of Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Older than 18; 2.The positive time of HBsAg was more than 6 months; 3.Patients who meet the antiviral diagnosis and treatment standards in the 2019 Chinese guidelines for the diagnosis and treatment of chronic hepatitis B and have not received or are receiving oral nucleoside (acid) antiviral drugs; 4.Chronic kidney disease was diagnosed according to KDIGO guidelines in 2012. Renal injury indexes (such as proteinuria, hematuria or anatomical abnormalities) or GFR 3 months; 5.Understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women; 2.With other types of hepatitis virus infection or HIV infection; 3.Patients with decompensated cirrhosis (Child B/C grade) or confirmed liver cancer or other malignant tumors; 4.Patients with glomerular filtration rate < 15 ml/min and without hemodialysis 5.Patients with mental illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| routine blood test;urinalysis;Urinary albumin / creatinine;liver function;renal function;electrolyte;Coagulation function;Hepatitis B three line quantitative analysis;Serum HBVDNA;Abdominal B-ultrasound examination;Liver transient elastic stiffness test;Bone mineral density test; | — |
Countries
China
Contacts
Public ContactQian Yunsong
Ningbo Huamei Hospital, University of Chinese Academy of Sciences
Outcome results
None listed